UBS lowered the firm’s price target on W. R. Berkley (WRB) to $71 from $75 and keeps a Neutral rating on the shares. Insurance brokers are well positioned for 2026, with organic revenue growth averaging 4.4% and EBITDA margins improving year over year despite property rate pressures, the analyst tells investors in a research note. With growth expectations reset and valuations reflecting a softer market, there is upside to consensus EPS and potential for multiple expansion, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WRB:
- W. R. Berkley price target lowered to $73 from $74 at Morgan Stanley
- W. R. Berkley Balances Record Earnings With Market Risks
- W. R. Berkley price target lowered to $80 from $84 at Truist
- W. R. Berkley price target lowered to $66 from $69 at BofA
- W. R. Berkley: Solid Underwriting but Slowing Growth and Limited Upside Justify Neutral (Hold) Rating